Premium
Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women
Author(s) -
WILSON P. D.,
FARAGHER B.,
BUTLER B.,
BU'LOCK D.,
ROBINSON E. L.,
BROWN A. D. G.
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb03152.x
Subject(s) - medicine , placebo , statistical significance , urology , hormone therapy , stress incontinence , postmenopausal women , placebo group , menopause , gynecology , urinary incontinence , breast cancer , cancer , alternative medicine , pathology
Summary The use of oestrogens in the treatment of genuine stress incontinence was assessed by a double‐blind prospective trial in 36 postmenopausal women with genuine stress incontinence who received 3 months of cyclical treatment with either piperazine oestrone sulphate or a matching placebo. Patients were assessed subjectively and objectively before and after treatment by 7‐day bladder charts, urethral pressure profiles (UPP), the Urilos nappy test, vaginal cytology and hormone assays (plasma oestrogens and gonadotrophins). There was no statistical difference in the subjective response to treatment between the two groups. After 6 weeks of treatment there was a greater reduction in the number of pad changes/24 h in the oestrogen‐treated patients that approached statistical significance but, because of a marked response in the placebo group, this difference was not significant after 3 months of treatment. There were also no significant differences between the two groups with respect to the UPP or Urilos measurements but the vaginal cytology and hormone profiles were significantly affected by oestrogens. In view of the possible risks of oestrogen therapy its use in genuine stress incontinence is limited.